Literature DB >> 10751255

Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates.

R Dabby1, L H Weimer, A P Hays, M Olarte, N Latov.   

Abstract

OBJECTIVE: To investigate the clinical and electrophysiologic characteristics of the neuropathy associated with elevated serum antisulfatide antibodies.
METHODS: Clinical, electrophysiologic, morphologic, and laboratory data of 25 patients with significantly elevated (>25,600) antisulfatide antibodies were reviewed.
RESULTS: Four groups were distinguished based on clinical and electrophysiologic data: Group 1, eight patients with predominantly small fiber sensory neuropathy (32%); Group 2, five patients with mixed large and small fiber sensory neuropathy (20%); Group 3, seven patients with axonal sensorimotor neuropathy (28%); and Group 4, three patients with demyelinating sensorimotor neuropathy (12%). One additional patient had mononeuritis multiplex and one had ALS. An immunoglobulin M (IgM) monoclonal gammopathy was found in 30% of the patients tested, but not in any of the Group 1 patients with small fiber sensory neuropathy. Serum IgM level was elevated in 12 patients, of whom six had a concomitant monoclonal gammopathy. Morphologic studies in five patients showed predominantly axonal degeneration, with three of the patients also exhibiting additional features of demyelination.
CONCLUSIONS: Antisulfatide antibodies are associated with several subtypes of peripheral neuropathy. Predominantly sensory or sensorimotor axonal neuropathies are most common in this series, with the sensory component either small fiber or mixed fiber type. A smaller demyelinating group indistinguishable from patients with chronic inflammatory demyelinating polyradiculopathy was also seen. One third of patients had a concomitant IgM monoclonal gammopathy, and approximately one half had elevated serum IgM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751255     DOI: 10.1212/wnl.54.7.1448

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Small-fibre neuropathies--advances in diagnosis, pathophysiology and management.

Authors:  Janneke G Hoeijmakers; Catharina G Faber; Giuseppe Lauria; Ingemar S Merkies; Stephen G Waxman
Journal:  Nat Rev Neurol       Date:  2012-05-29       Impact factor: 42.937

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 3.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

4.  Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

Authors:  Luisa M Villar; María C Sádaba; Ernesto Roldán; Jaime Masjuan; Pedro González-Porqué; Noelia Villarrubia; Mercedes Espiño; José A García-Trujillo; Alfredo Bootello; José C Alvarez-Cermeño
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 5.  Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.

Authors:  Johannes J Roggenbuck; Joseph Boucraut; Emilien Delmont; Karsten Conrad; Dirk Roggenbuck
Journal:  Ann Transl Med       Date:  2018-09

6.  Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial.

Authors:  Bianca T A de Greef; Margot Geerts; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies
Journal:  Trials       Date:  2016-07-20       Impact factor: 2.279

7.  Chronic Inflammatory or Chronic Inflammatory Demyelinating Polyradiculoneuropathy?

Authors:  Jean-Michel Vallat; Nathalie Deschamps; Philippe Corcia; Laurent Magy; Stéphane Mathis
Journal:  Front Neurol       Date:  2022-04-04       Impact factor: 4.003

8.  Novel Autoantibodies in Idiopathic Small Fiber Neuropathy.

Authors:  Amanda C Y Chan; Hiu Yi Wong; Yao Feng Chong; Poh San Lai; Hock Luen Teoh; Alison Y Y Ng; Jennifer H M Hung; Yee Cheun Chan; Kay W P Ng; Joy Vijayan; Jonathan J Y Ong; Bharatendu Chandra; Chi Hsien Tan; Nurul H Rutt; Ti Myen Tan; Nur Hafiza Ismail; Einar Wilder-Smith; Herbert Schwarz; Hyungwon Choi; Vijay K Sharma; Anselm Mak
Journal:  Ann Neurol       Date:  2021-12-01       Impact factor: 11.274

9.  Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy.

Authors:  Margot Geerts; Bianca T A de Greef; Maurice Sopacua; Sander M J van Kuijk; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies
Journal:  Neurology       Date:  2021-03-25       Impact factor: 9.910

Review 10.  Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing.

Authors:  Dirk Roggenbuck; Emilien Delmont; Dirk Reinhold; Peter Schierack; Karsten Conrad; Joseph Boucraut
Journal:  Mediterr J Rheumatol       Date:  2020-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.